RU2005102484A - Слитые белки hcv c модифицированными доменами ns3 - Google Patents
Слитые белки hcv c модифицированными доменами ns3 Download PDFInfo
- Publication number
- RU2005102484A RU2005102484A RU2005102484/13A RU2005102484A RU2005102484A RU 2005102484 A RU2005102484 A RU 2005102484A RU 2005102484/13 A RU2005102484/13 A RU 2005102484/13A RU 2005102484 A RU2005102484 A RU 2005102484A RU 2005102484 A RU2005102484 A RU 2005102484A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- modified
- asp
- inhibited
- ser
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 11
- 108090000623 proteins and genes Proteins 0.000 title claims 11
- 229920001184 polypeptide Polymers 0.000 claims 160
- 102000004196 processed proteins & peptides Human genes 0.000 claims 160
- 108090000765 processed proteins & peptides Proteins 0.000 claims 160
- 108091005804 Peptidases Proteins 0.000 claims 22
- 239000004365 Protease Substances 0.000 claims 22
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 238000006467 substitution reaction Methods 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 19
- 102000037865 fusion proteins Human genes 0.000 claims 19
- 201000005505 Measles Diseases 0.000 claims 10
- 108010076039 Polyproteins Proteins 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 230000024932 T cell mediated immunity Effects 0.000 claims 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39369402P | 2002-07-02 | 2002-07-02 | |
| US60/393,694 | 2002-07-02 | ||
| US39451002P | 2002-07-08 | 2002-07-08 | |
| US60/394,510 | 2002-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005102484A true RU2005102484A (ru) | 2006-01-20 |
Family
ID=30118384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005102484/13A RU2005102484A (ru) | 2002-07-02 | 2003-07-02 | Слитые белки hcv c модифицированными доменами ns3 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1539809A4 (de) |
| JP (2) | JP2005532064A (de) |
| CN (1) | CN1678630A (de) |
| AU (1) | AU2003248818A1 (de) |
| CA (1) | CA2491508A1 (de) |
| PL (1) | PL374349A1 (de) |
| RU (1) | RU2005102484A (de) |
| WO (1) | WO2004005473A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491808B2 (en) * | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| AU2003287188A1 (en) * | 2002-10-25 | 2004-05-25 | Chiron Corporation | Activation of hcv-specific cells |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| JP2007537757A (ja) * | 2004-05-17 | 2007-12-27 | カイロン コーポレーション | 切断ｃ型肝炎ｎｓ５ドメインおよびこれを含む融合タンパク質 |
| JP5070055B2 (ja) * | 2004-08-27 | 2012-11-07 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 改変タンパク分解性切断部位を有するｈｃｖ多エピトープ融合抗原およびその使用 |
| CN102614510A (zh) * | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US7968697B2 (en) * | 2005-05-25 | 2011-06-28 | Chrontech Pharma Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
| US20090238822A1 (en) * | 2005-10-13 | 2009-09-24 | Virexx Medical Corp. | Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response |
| GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| US8216590B2 (en) * | 2006-08-25 | 2012-07-10 | Novartis Ag | HCV fusion polypeptides |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| US9321847B2 (en) | 2010-09-20 | 2016-04-26 | Ramot At Tel Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| WO2016160046A1 (en) * | 2015-03-27 | 2016-10-06 | Ortho-Clinical Diagnostics, Inc. | Hcv ns4a/modified ns3 polypeptides and uses thereof |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| CN111153963B (zh) * | 2020-01-19 | 2021-08-10 | 华南理工大学 | 抗炎五肽及其提取分离方法和在改善记忆中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69432475T2 (de) * | 1993-11-04 | 2004-03-04 | Innogenetics N.V. | Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis |
| JP2003516732A (ja) * | 1999-11-24 | 2003-05-20 | カイロン コーポレイション | 新規なｈｃｖ非構造ポリペプチド |
| WO2001090812A1 (en) * | 2000-05-23 | 2001-11-29 | Massachusetts Institute Of Technology | Ultraviolet fluoride nonlinear devices |
-
2003
- 2003-07-02 PL PL03374349A patent/PL374349A1/xx not_active Application Discontinuation
- 2003-07-02 CN CNA038207192A patent/CN1678630A/zh active Pending
- 2003-07-02 EP EP03763172A patent/EP1539809A4/de not_active Withdrawn
- 2003-07-02 RU RU2005102484/13A patent/RU2005102484A/ru not_active Application Discontinuation
- 2003-07-02 JP JP2004519849A patent/JP2005532064A/ja active Pending
- 2003-07-02 CA CA002491508A patent/CA2491508A1/en not_active Abandoned
- 2003-07-02 AU AU2003248818A patent/AU2003248818A1/en not_active Abandoned
- 2003-07-02 WO PCT/US2003/020996 patent/WO2004005473A2/en not_active Ceased
-
2006
- 2006-06-23 JP JP2006174595A patent/JP2006265267A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1539809A4 (de) | 2006-03-08 |
| JP2006265267A (ja) | 2006-10-05 |
| WO2004005473A2 (en) | 2004-01-15 |
| CN1678630A (zh) | 2005-10-05 |
| AU2003248818A1 (en) | 2004-01-23 |
| CA2491508A1 (en) | 2004-01-15 |
| EP1539809A2 (de) | 2005-06-15 |
| WO2004005473A3 (en) | 2004-04-01 |
| PL374349A1 (en) | 2005-10-17 |
| JP2005532064A (ja) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005102484A (ru) | Слитые белки hcv c модифицированными доменами ns3 | |
| JP2008516610A5 (de) | ||
| JP2005532064A5 (de) | ||
| Eckart et al. | The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor | |
| Pizzi et al. | Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. | |
| CA2390082A1 (en) | Novel hcv non-structural polypeptide | |
| Arias et al. | Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain | |
| Failla et al. | Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins | |
| Nowak et al. | Analyses of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis | |
| Ralston et al. | Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses | |
| Lin et al. | The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins | |
| Lanford et al. | Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells | |
| Ryan et al. | Virus-encoded proteinases of the Flaviviridae. | |
| FI107610B (fi) | HCV-fuusioproteiini | |
| Hirowatari et al. | Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector | |
| CA2584228A1 (en) | Vaccines against japanese encephalitis virus and west nile virus | |
| JP2006518331A5 (de) | ||
| YU48038B (sh) | Postupak za dijagnostiku ne-a, ne-v hepatitisa | |
| Mizuno et al. | Virion-like structures in HeLa G cells transfected with the full-length sequence of the hepatitis C virus genome | |
| CA2623329A1 (en) | Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response | |
| RU2005118998A (ru) | Полипептиды и конъюгаты альфа-интерферона | |
| RU2005113692A (ru) | Вакцина против hcv | |
| RU2006144714A (ru) | Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки | |
| CA2220729C (en) | Method for refolding insoluble aggregates of hepatitis c virus protease | |
| Khumthong et al. | In vitro determination of dengue virus type 2 NS2B-NS3 protease activity with fluorescent peptide substrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070827 |